desmethylselegiline

Known as: demethyl-deprenyl-DMD, di-N-propargylamphetamine, N-desmethyl-selegiline 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1993-2008
024619932008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
We devised a highly sensitive method for simultaneously determining methamphetamine (MA) and amphetamine (AP) enantiomers… (More)
Is this relevant?
2003
2003
Selegiline, a therapeutic agent of Parkinson's disease, and its metabolite, desmethylselegiline, were explored for their… (More)
Is this relevant?
2001
2001
The development of transgenic mouse models of amyotrophic lateral sclerosis (ALS) allows the testing of neuroprotective agents… (More)
Is this relevant?
2000
2000
We investigated the effects of selegiline and desmethylselegiline on synthesis of neurotrophic factors in cultured mouse… (More)
Is this relevant?
2000
2000
The paper provides an interdisciplinary evaluation of the etiology, pathogenesis, and experimental treatments of retinitis… (More)
Is this relevant?
2000
2000
The goal of this study was to examine the multiple-dose pharmacokinetics of selegiline and its metabolites desmethylselegiline, 1… (More)
Is this relevant?
1998
1998
Oxidative stress is thought to play an important role in the pathogenesis of Parkinson's disease (PD). Glutathione (GSH), a major… (More)
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
1997
1997
Selegiline, an irreversible and selective inhibitor of monoamine oxidase type B (MAO-B), is metabolized into desmethylselegiline… (More)
Is this relevant?
1997
1997
Selegiline [L-(-)-deprenyl], a monoamine oxidase B inhibitor, has been used in the treatment of Parkinson's disease as a putative… (More)
Is this relevant?
1993
1993
A sensitive and specific assay for the quantitative determination of amphetamine, methamphetamine and desmethyldeprenyl in human… (More)
Is this relevant?